According to HC Wainwright research analysts, Zynex (NSD: ZYXI) is predicted to earn $0.07 per share for the second quarter of 2023, which is lower than their previous estimate of $0.09. HC Wainwright has given the ZYXI stock a “Buy” rating and set a price target of $20.00. The consensus forecast for Zynex’s full-year earnings is $0.46 per share. HC Wainwright also provided estimates for Zynex’s Q4 2023 earnings at $0.23 EPS and FY2023 earnings at $0.45 EPS.
In the company’s latest earnings report on March 13th, Zynex reported earnings of $0.20 per share for the quarter, exceeding the consensus estimate of $0.19 by $0.01. During the quarter, the company generated $48.81 million in revenue, compared to analyst estimates of $49.65 million. Zynex’s net margin was 10.78%, and its return on equity was 24.35%.
Zynex’s Earnings Growth
Zynex’s stock (NSD: ZYXI) started trading on Thursday at $10.76, a decrease of 2.2%. The company’s one year low is $5.35, and its one year high is $17.25. Zynex has market capitalization of $402.77 million, a price-to-earnings ratio of 24.44. The company’s debt-to-equity ratio is 0.10, its current ratio is 3.41, and its quick ratio is 2.68. Zynex’s 50-day and 200-day simple moving averages are $13.50 and $12.13, respectively. A number of hedge funds and other institutional investors have recently purchased and sold shares of ZYXI, with hedge funds and other institutional investors owning 28.64% of the company’s stock.
Zynex Inc Stock Analysis
According to three analysts’ forecasts for Zynex Inc’s stock, the average analyst target price for the next 12 months is USD 15.38, and the company’s average analyst ratings is Strong Buy. Stock Target Advisor’s own analysis of Zynex Inc’s stock is Slightly Bullish, based on 10 positive signals and 6 negative signals. The closing stock price of Zynex Inc. was USD 10.76. Over the past week, the stock price has risen by +11.34%, while over the past month, it has fallen by -16.56%. However, over the last year, the stock price has increased by +100.28%.
Zynex, Inc. is a medical device company that develops, manufactures, and sells devices to treat chronic and acute pain, as well as devices for muscle activation and rehabilitation through electrical stimulation. Its products include NexWave, NeuroMove, InWave, and E-Wave devices, as well as private-labeled products such as electrodes and batteries for electrotherapy. The company also distributes cervical traction, hot/cold therapy, lumbar support, and knee braces. Additionally, Zynex offers fluid volume monitoring devices for use in operating and recovery rooms, as well as devices for hemodynamic monitoring and pulse oximetry. The company primarily sells its products in the United States through a direct sales force.